Skip to main content
Premium Trial:

Request an Annual Quote

Hoechst-Ariad Genomics Center Gets Molecular's Microarray Technologies

Premium

CAMBRIDGE, Mass.--Molecular Dynamics and Amersham Pharmacia announced that the Hoechst-ARIAD Genomics Center here will collaborate with the two firms for continued development of new microarray technologies. Under the agreement, the center will provide funding and technical expertise while gaining early access to integrated microarray systems, related support, and training programs jointly developed by Molecular Dynamics and Amersham Pharmacia.

The center's researchers will receive microarray spotting and optical scanning instrumentation and software from Molecular Dynamics along with matched reagents and consumables from Amersham. Designed to help measure gene expression, identify new pharmaceutical targets, and measure therapeutic response, the microarray technology will directly support the Genomics Center's efforts to identify novel targets for small-molecule drug discovery and therapeutic proteins.

Filed under

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.